COVID-19 and the Global Impact on Colorectal Practice and Surgery.

Abstract:

BACKGROUND:The novel severe acute respiratory syndrome coronavirus 2 virus that emerged in December 2019 causing coronavirus disease 2019 (COVID-19) has led to the sudden national reorganization of health care systems and changes in the delivery of health care globally. The purpose of our study was to use a survey to assess the global effects of COVID-19 on colorectal practice and surgery. MATERIALS AND METHODS:A panel of International Society of University Colon and Rectal Surgeons (ISUCRS) selected 22 questions, which were included in the questionnaire. The questionnaire was distributed electronically to ISUCRS fellows and other surgeons included in the ISUCRS database and was advertised on social media sites. The questionnaire remained open from April 16 to 28, 2020. RESULTS:A total of 287 surgeons completed the survey. Of the 287 respondents, 90% were colorectal specialists or general surgeons with an interest in colorectal disease. COVID-19 had affected the practice of 96% of the surgeons, and 52% were now using telemedicine. Also, 66% reported that elective colorectal cancer surgery could proceed but with perioperative precautions. Of the 287 respondents, 19.5% reported that the use of personal protective equipment was the most important perioperative precaution. However, personal protective equipment was only provided by 9.1% of hospitals. In addition, 64% of surgeons were offering minimally invasive surgery. However, 44% reported that enough information was not available regarding the safety of the loss of intra-abdominal carbon dioxide gas during the COVID-19 pandemic. Finally, 61% of the surgeons were prepared to defer elective colorectal cancer surgery, with 29% willing to defer for ≤ 8 weeks. CONCLUSION:The results from our survey have demonstrated that, globally, COVID-19 has affected the ability of colorectal surgeons to offer care to their patients. We have also discussed suggestions for various practical adaptation strategies for use during the recovery period.

journal_name

Clin Colorectal Cancer

authors

Nunoo-Mensah JW,Rizk M,Caushaj PF,Giordano P,Fortunato R,Dulskas A,Bugra D,da Costa Pereira JM,Escalante R,Koda K,Samalavicius NE,Maeda K,Chun HK,ISUCRS COVID-19 Participating Investigator Group.

doi

10.1016/j.clcc.2020.05.011

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

178-190.e1

issue

3

eissn

1533-0028

issn

1938-0674

pii

S1533-0028(20)30084-0

journal_volume

19

pub_type

杂志文章
  • Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy.

    abstract::Primary squamous cell colorectal carcinomas are uncommon, and their characteristics are not well known. They seem to occur most commonly in the fifth decade of life with a slight predominance for men. The most commonly reported anatomic locations are the rectum and the proximal colon. Clinical features and common diag...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2001.n.006

    authors: Copur S,Ledakis P,Novinski D,Mleczko KL,Frankforter S,Bolton M,Fruehling RM,VanWie E,Norvell M,Muhvic J

    更新日期:2001-05-01 00:00:00

  • Preclinical data targeting vascular endothelial growth factor in colorectal cancer.

    abstract::Vascular endothelial growth factor (VEGF) is the driving force behind angiogenesis in most solid malignancies. This also holds true for colorectal cancer (CRC), where increased levels of VEGF in primary cancers are associated with increased microvessel density and poor prognosis. These findings have led to preclinical...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/ccc.2004.s.009

    authors: Ellis LM

    更新日期:2004-10-01 00:00:00

  • Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.

    abstract:INTRODUCTION:In studies of colorectal cancer, the elderly have been frequently underrepresented because comorbid conditions and functional status often lead to study exclusion. For elderly patients with an indication for neoadjuvant chemoradiotherapy (nCRT), physicians usually decide using clinical factors whether nCRT...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.03.004

    authors: Jacobs L,van der Vlies E,Ten Bokkel Huinink D,Bloemendal H,Intven M,Smits AB,Weusten BLAM,Siersema PD,van Lelyveld N,Los M

    更新日期:2018-09-01 00:00:00

  • Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer.

    abstract::Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical activities inadequate if based only on the reduction of the tumor dimensions, as this may not reflect thei...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clcc.2014.12.002

    authors: Manzoni M,Comolli G,Torchio M,Mazzini G,Danova M

    更新日期:2015-03-01 00:00:00

  • Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders.

    abstract:BACKGROUND:The primary objective of this study was to determine the long-term outcome of sphincter preservation with preoperative radiation therapy (RT) and surgical resection in the treatment of distal rectal adenocarcinoma. PATIENTS AND METHODS:Between April 1988 and December 1996, 36 (cT2, n=9; cT3, n=27) patients ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2006.n.012

    authors: Rengan R,Paty PB,Wong WD,Guillem JG,Weiser M,Temple L,Saltz L,Minsky BD

    更新日期:2006-03-01 00:00:00

  • Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.

    abstract:BACKGROUND:We performed a meta-analysis of previous reports evaluating the effect of mFIO (modified FOLFIRINOX; leucovorin, 5-fluorouracil, irinotecan, oxaliplatin) regimens in advanced pancreatic cancer. MATERIALS AND METHODS:We performed a meta-analysis of reported studies in PubMed, Scopus, and Web of Science (1950...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clcc.2018.03.007

    authors: Usón Junior PLS,Rother ET,Maluf FC,Bugano DDG

    更新日期:2018-09-01 00:00:00

  • Patients with colorectal and renal cell carcinoma diagnoses appear to be at risk for additional malignancies.

    abstract:UNLABELLED:Patients with colorectal cancer (CRC) and renal cell carcinoma (RCC) may be at risk for additional primary malignancies. A review of 101 patients with these concurrent diagnoses was performed. Forty-two percent of patients had 1 or more additional malignancies; none appeared to be associated with Lynch syndr...

    journal_title:Clinical colorectal cancer

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.clcc.2012.07.004

    authors: Steinhagen E,Moore HG,Lee-Kong SA,Shia J,Eaton A,Markowitz AJ,Russo P,Guillem JG

    更新日期:2013-03-01 00:00:00

  • Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.

    abstract:BACKGROUND:ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or trastuzumab and pertuzumab. We present long-term clinical results of trastuzumab and lapatinib (HERACLES-A...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2020.06.009

    authors: Tosi F,Sartore-Bianchi A,Lonardi S,Amatu A,Leone F,Ghezzi S,Martino C,Bencardino K,Bonazzina E,Bergamo F,Fenocchio E,Martinelli E,Troiani T,Siravegna G,Mauri G,Torri V,Marrapese G,Valtorta E,Cassingena A,Cappello G

    更新日期:2020-12-01 00:00:00

  • Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age.

    abstract:BACKGROUND:Screening protocols for colorectal cancer are broadly recommended and effective in reducing mortality. However, populations from different age groups can harbor distinct pathologic and molecular profiles that can also be influenced by screening and polyp resection, especially in older ages. PATIENTS AND MET...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2020.06.004

    authors: Pereira AAL,Fernandes GDS,Braga GTP,Marchetti KR,Mascarenhas CDC,Gumz B,Crosara M,Dib L,Girardi D,Barrichello A,Seidler H

    更新日期:2020-12-01 00:00:00

  • The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.

    abstract:BACKGROUND:Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is used as monotherapy for chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type (WT) KRAS tumors. Although skin toxicities are the most common adverse events associated with EGFR in...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clcc.2011.06.004

    authors: Mitchell EP,Piperdi B,Lacouture ME,Shearer H,Iannotti N,Pillai MV,Xu F,Yassine M

    更新日期:2011-12-01 00:00:00

  • Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System.

    abstract:BACKGROUND:Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. MATERIALS AND METHODS:The Harris Health System (HHS) is an integrated health delivery network that provides medical car...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2019.09.002

    authors: Lau-Min K,Prakash P,Jo E,Thrift AP,Hilsenbeck S,Musher BL

    更新日期:2020-06-01 00:00:00

  • Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.

    abstract::Combination protocols of 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan or oxaliplatin have demonstrated high activity in metastatic colorectal cancer. Capecitabine, an oral 5-FU prodrug, may replace infusional 5-FU/LV in combination protocols with irinotecan or oxaliplatin. We therefore initiated a phase II stud...

    journal_title:Clinical colorectal cancer

    pub_type: 临床试验,杂志文章

    doi:10.3816/ccc.2004.n.009

    authors: Jordan K,Kellner O,Kegel T,Schmoll HJ,Grothey A

    更新日期:2004-05-01 00:00:00

  • Laparoscopic radical correction combined with extensive lymphadenectomy and pelvic autonomic nerve preservation for mid-to-low rectal cancer.

    abstract:OBJECTIVE:The purposes of this study were to confirm the definite metastasis and micrometastasis rate of upward and lateral lymph nodes of mid-to-low rectal cancer at stage II and stage III, and to evaluate the feasibility and safety of laparoscopic radical correction combined with extensive lymphadenectomy and pelvic ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2011.03.025

    authors: Liu T,Zhang C,Yu P,Chen J,Zeng D,Gan L,Lv W,Liu L,Yan X

    更新日期:2011-09-01 00:00:00

  • Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.

    abstract:PURPOSE:The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations. Capecitabine is also at least as effective as bolus 5-FU/LV i...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/ccc.2005.n.021

    authors: Twelves CJ,Butts CA,Cassidy J,Conroy T,Braud Fd,Diaz-Rubio E,Tabernero JM,Schoffski P,Figer A,Brunet R,Grossmann J,Sobrero AF,Van Cutsem EJ

    更新日期:2005-07-01 00:00:00

  • First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.

    abstract:BACKGROUND:Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC. PATIENTS AND METHODS:Using a modified Simon accelerated titration design, adults with...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2020.08.003

    authors: Winer A,Denlinger CS,Vijayvergia N,Cohen SJ,Astaturov I,Dotan E,Gallant JN,Wang EW,Kunkel M,Lim B,Harvey HA,Sivik J,Korzekwa K,Ruth K,White K,Cooper HS,Ross EA,Zhou L,El-Deiry WS

    更新日期:2020-08-19 00:00:00

  • Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.

    abstract::Bevacizumab is a humanized monoclonal antibody approved by the US Food and Drug Administration for use in combination with fluorouracil (FU)-based chemotherapy for first-line treatment of patients with metastatic colorectal carcinoma (CRC). Its mechanism of action is inhibition of tumor angiogenesis by neutralizing va...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2010.n.008

    authors: Gamboa EO,Rehmus EH,Haller N

    更新日期:2010-01-01 00:00:00

  • A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.

    abstract:PURPOSE:Capecitabine has shown similar efficacy to 5-fluorouracil (5-FU); a regimen containing 2 weeks of capecitabine/oxaliplatin (CapOx) has demonstrated noninferiority to infusional 5-FU/oxaliplatin/leucovorin (FOLFOX) for the treatment of metastatic colorectal cancer (mCRC). This phase II study explores the efficac...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2010.n.021

    authors: Lubner SJ,Loconte NK,Holen KD,Schelman W,Thomas JP,Jumonville A,Eickhoff JC,Seo S,Mulkerin DL

    更新日期:2010-07-01 00:00:00

  • Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry.

    abstract:BACKGROUND:Colorectal cancer (CRC) is a common malignancy. There is growing evidence that CRC incidence is increasing in the younger population. There is controversy surrounding the prognosis of young patients with CRC. In this study we reviewed Australian patients with metastatic CRC (mCRC) who were younger than 40 ye...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2015.07.005

    authors: Vatandoust S,Price TJ,Ullah S,Roy AC,Beeke C,Young JP,Townsend A,Padbury R,Roder D,Karapetis CS

    更新日期:2016-03-01 00:00:00

  • Is levoleucovorin an alternative to racemic leucovorin? A literature review.

    abstract:PURPOSE:Our purpose is to perform a comprehensive literature review of the use of levoleucovorin in gastrointestinal malignancies and to assess whether levoleucovorin is a reasonable alternative to racemic leucovorin. DESIGN:This is an extensive literature review of levoleucovorin use in patients with gastrointestinal...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2009.n.034

    authors: Kovoor PA,Karim SM,Marshall JL

    更新日期:2009-10-01 00:00:00

  • Diverticular disease in patients with colon cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06.

    abstract:BACKGROUND:Similar epidemiologic characteristics suggest a common etiology for colon cancer (CC) and diverticular disease of the colon (DD). The relationship between the 2 diseases is still unclear, and the impact of DD in patients diagnosed with CC on disease-free survival (DFS) and overall survival (OS) is unknown. N...

    journal_title:Clinical colorectal cancer

    pub_type: 临床试验,杂志文章

    doi:10.3816/ccc.2006.n.031

    authors: Soran A,Harlak A,Wilson JW,Nesbitt L,Lembersky BC,Wienad HS,O'Connell MJ

    更新日期:2006-07-01 00:00:00

  • Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.

    abstract::Modern chemotherapy combinations for metastatic colorectal cancer (mCRC) comprise infusional 5-fluorouracil (5-FU), leucovorin, and irinotecan or oxaliplatin. The fluoropyrimidine derivative capecitabine is at least as effective as 5-FU plus leucovorin bolus regimens. It displays a favorable toxicity profile and offer...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2008.n.015

    authors: Moosmann N,Heinemann V

    更新日期:2008-03-01 00:00:00

  • Spindle Assembly Checkpoint as a Potential Target in Colorectal Cancer: Current Status and Future Perspectives.

    abstract::Colorectal cancer (CRC), one of the most common malignancies worldwide, is often diagnosed at an advanced stage, and resistance to chemotherapeutic and existing targeted therapy is a major obstacle to its successful treatment. New targets that offer alternative clinical options are therefore urgently needed. Recently,...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clcc.2016.06.006

    authors: Diogo V,Teixeira J,Silva PM,Bousbaa H

    更新日期:2017-03-01 00:00:00

  • Locoregional strategies for colorectal hepatic metastases.

    abstract::Hepatic colorectal metastases present a challenging problem in patients with recurrent colorectal cancer. Twenty percent of patients with recurrence will have liver metastases as a component of their disease, and only 10% of these patients will have isolated liver metastases that are resectable. Although systemic chem...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2003.n.010

    authors: Meyers MO,Sasson AR,Sigurdson ER

    更新日期:2003-05-01 00:00:00

  • Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

    abstract:BACKGROUND:Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-r...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.08.002

    authors: Sunakawa Y,Yang D,Cao S,Zhang W,Moran M,Astrow SH,Hsiang J,Stephens C,Tsuji A,Takahashi T,Tanioka H,Negoro Y,Takagane A,Tani S,Yamaguchi T,Eto T,Fujii M,Ichikawa W,Lenz HJ

    更新日期:2018-12-01 00:00:00

  • Local excision for rectal carcinoma.

    abstract::Local excision is an alternative approach to radical proctectomy for rectal cancer, but from an oncologic standpoint, it is a compromise, and its role remains controversial. Careful patient selection is essential because local excision is generally considered only for early rectal cancer with no evidence of nodal meta...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2008.n.050

    authors: Kim E,Hwang JM,Garcia-Aguilar J

    更新日期:2008-11-01 00:00:00

  • Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer.

    abstract::Epidermal growth factor receptor (EGFR) has been validated as an important target in the treatment of metastatic colorectal cancer (mCRC). While initial studies focused on the treatment of disease that was refractory to available chemotherapy agents, 2 recent themes have emerged: the use of KRAS mutation status to sel...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2010.s.006

    authors: Stein S,Cohen DJ,Hochster HS

    更新日期:2010-06-01 00:00:00

  • Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.

    abstract::Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal cancer of teh gastrointestinal tract. They are characterized by the expression of KIT. Therapeutically, metastatic GISTs are effectively treated by imatinib, a tyrosine kinase inhibitor (TKI) with activity against KIT and platelet-derived growth f...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/ccc.2006.s.005

    authors: von Mehren M

    更新日期:2006-11-01 00:00:00

  • Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.

    abstract:BACKGROUND:The safety of bevacizumab in older mCRC patients is poorly understood. The purpose of this analysis was to determine the prevalence, incidence, and risk factors for treatment-related AEs in older bevacizumab recipients. PATIENTS AND METHODS:Patients age ≥65 were identified from SEER-Medicare and categorized...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2012.11.004

    authors: Shankaran V,Mummy D,Koepl L,Blough D,Yim YM,Yu E,Ramsey S

    更新日期:2013-09-01 00:00:00

  • Intussusception in colorectal cancer.

    abstract::Adult intussusception is a rare occurrence and, unlike in childhood, is usually associated with an underlying tumor. Although computed tomography (CT) imaging can identify an intussusception and point toward a cause, diagnosis is challenging if it is only intermittent. When an intussusception presents in the context o...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2008.n.028

    authors: Chand M,Bradford L,Nash GF

    更新日期:2008-05-01 00:00:00

  • Positron emission tomography for the evaluation of patients with colorectal cancer.

    abstract::Approximately 40% of patients treated with curative intent for colorectal carcinoma eventually recur. In about one third of these patients, the lesion is localized and potentially resectable. Typically, the recurrence is characterized by findings on diagnostic imaging studies and may be accompanied by a rise in the se...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2001.n.012

    authors: Fogarasi MC,Zelkowitz RS,Messana SA,Arrighi JA,Seibyl JP,Kummar S

    更新日期:2001-08-01 00:00:00